Citation Impact
Citing Papers
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
2011 Standout
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
2005 StandoutScience
Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)
2010
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
2013 StandoutScienceNobel
Stable Expression of Recombinant Factor VIII Molecules Using a Bovine Papillomavirus Vector
1987
Multiple myeloma associated with diffuse osteosclerotic bone lesions: A clinical entity distinct from osteosclerotic myeloma (POEMS syndrome)
1997
Mechanisms, regulation and functions of the unfolded protein response
2020 Standout
PROGNOSTIC FACTORS IN MULTIPLE MYELOMA
1999
Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase
1988 Standout
MYC on the Path to Cancer
2012 Standout
Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu
2008 StandoutNature
A novel arachidonic acid-selective cytosolic PLA2 contains a Ca2+-dependent translocation domain with homology to PKC and GAP
1991 Standout
Clinical Course of Patients With Relapsed Multiple Myeloma
2004
Chapter 18 Oligodendrocyte regeneration in the adult rodent CNS and the failure of this process in multiple sclerosis
1998
High-dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma.
1994
Multiple sclerosis: a unique immunopathological syndrome of the central nervous system
1995
TNFα promotes proliferation of oligodendrocyte progenitors and remyelination
2001
Expression monitoring by hybridization to high-density oligonucleotide arrays
1996 Standout
The molecular basis of blood coagulation
1988 Standout
A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma
1996 Standout
Monoclonal remyelination-promoting natural autoantibody SCH 94.03: pharmacokinetics and in vivo targets within demyelinated spinal cord in a mouse model of multiple sclerosis
1997
Repertoire of microglial and macrophage responses after spinal cord injury
2011 Standout
Multiple sclerosis
2008 Standout
Super-Enhancers in the Control of Cell Identity and Disease
2013 Standout
Induction of a Chronic Disease State in Patients With Smoldering or Indolent Multiple Myeloma by Targeting Interleukin 1β-Induced Interleukin 6 Production and the Myeloma Proliferative Component
2009
Mutation in blood coagulation factor V associated with resistance to activated protein C
1994 StandoutNature
Immunity, Inflammation, and Cancer
2010 Standout
Remyelination in the CNS: from biology to therapy
2008
Methods for estimation of bone marrow plasma cell involvement in myeloma: Predictive value for response and survival in patients undergoing autologous stem cell transplantation
2001
High Serum Lactate Dehydrogenase Level as a Marker for Drug Resistance and Short Survival in Multiple Myeloma
1991
Characterization of the G Protein-coupled Receptor Kinase GRK4
1996 StandoutNobel
pRRophetic: An R Package for Prediction of Clinical Chemotherapeutic Response from Tumor Gene Expression Levels
2014 Standout
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma
2008
Review of 1027 Patients With Newly Diagnosed Multiple Myeloma
2003 Standout
The Management of Neoplastic Disorders of Haematopoeisis in Children with Down's Syndrome
2000
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
1999 Standout
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
2001 Standout
Down's syndrome
2003 Standout
Mechanisms of Bone Metastasis
2004 Standout
Efficacy and Safety of Pegylated Liposomal Doxorubicin in Combination With Bortezomib for Multiple Myeloma: Effects of Adverse Prognostic Factors on Outcome
2011
Liposomal drug delivery systems: From concept to clinical applications
2012 Standout
The Pathobiology of Vascular Dementia
2013 Standout
High-risk multiple myeloma treated with high-dose melphalan.
1992
Phosphatidylinositol 4,5-Bisphosphate (PIP2)-enhanced G Protein-coupled Receptor Kinase (GRK) Activity: LOCATION, STRUCTURE, AND REGULATION OF THE PIP2 BINDING SITE DISTINGUISHES THE GRK SUBFAMILIES
1996 StandoutNobel
Immunofluorescence Labeling Indices in Myeloma and Related Monoclonal Gammopathies
1987
Increased serum levels of β2m‐free HLA class I heavy chain in multiple myeloma
1999
Multiple sclerosis
2002 Standout
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells
1998 StandoutNature
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
2003 Standout
BIOCHEMISTRY AND GENETICS OF VON WILLEBRAND FACTOR
1998 Standout
Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma [see comments]
1996
Importance of a novel GABAA receptor subunit for benzodiazepine pharmacology
1989 StandoutNature
Distribution of von Willebrand factor in porcine intima varies with blood vessel type and location.
1987
Molecular cloning of a cDNA encoding human antihaemophilic factor
1984 Nature
Activated Platelets Release Two Types of Membrane Vesicles: Microvesicles by Surface Shedding and Exosomes Derived From Exocytosis of Multivesicular Bodies and -Granules
1999 Standout
Structural features in eukaryotic mRNAs that modulate the initiation of translation.
1991 Standout
Collagen-induced exposure of anionic phospholipid in platelets and platelet-derived microparticles.
1991
Functionally active targeting domain of the beta-adrenergic receptor kinase: an inhibitor of G beta gamma-mediated stimulation of type II adenylyl cyclase.
1994 StandoutNobel
Multiple Myeloma
2010
Improved survival in multiple myeloma and the impact of novel therapies
2007 Standout
Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.
1993 Standout
Biology of Oligodendrocyte and Myelin in the Mammalian Central Nervous System
2001 Standout
A novel membrane antigen selectively expressed on terminally differentiated human B cells
1994
Novel Regulators of Bone Formation: Molecular Clones and Activities
1988 StandoutScience
Criteria for the Diagnosis of Acute Leukemia of Megakaryocyte Lineage (M7)
1985
A new staging system for multiple myeloma based on the number of S- phase plasma cells
1995
Plasmablastic Morphology—An Independent Prognostic Factor With Clinical and Laboratory Correlates: Eastern Cooperative Oncology Group (ECOG) Myeloma Trial E9486 Report by the ECOG Myeloma Laboratory Group
1998
Real time quantitative PCR.
1996 Standout
Bortezomib: Proteasome Inhibition as an Effective Anticancer Therapy
2006
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells
2002
Increased Frequency of Surface IgA-Positive Plasma Cells in the Intestinal Lamina Propria and Decreased IgA Excretion in Hyper IgA (HIGA) Mice, a Murine Model of IgA Nephropathy with Hyperserum IgA
2000 StandoutNobel
Characterization of an interaction between protein C and ceruloplasmin.
1990
Association of the factor VIII light chain with von Willebrand factor.
1988
Diverse karyotypic abnormalities of the c -myc locus associated with c -myc dysregulation and tumor progression in multiple myeloma
2000
High levels of interleukin-6 are associated with low tumor burden and low growth fraction in multiple myeloma
1994
Antagonism of Catecholamine Receptor Signaling by Expression of Cytoplasmic Domains of the Receptors
1993 StandoutScienceNobel
Identification and characterization of plasma cells in normal human bone marrow by high-resolution flow cytometry
1990
Standard Chemotherapy Compared With High-Dose Chemoradiotherapy for Multiple Myeloma: Final Results of Phase III US Intergroup Trial S9321
2006
Establishment of a novel human megakaryoblastic leukemia cell line, MEG- 01, with positive Philadelphia chromosome
1985
Multiple Myeloma
2011 Standout
CD8+ T Cells Are a Biologically Relevant Source of Macrophage Inflammatory Protein-1α In Vivo
1999 StandoutNobel
A functional γ gene formed from known γ-gene segments is not necessary for antigen-specific responses of murine cytotoxic T lymphocytes
1986 StandoutNatureNobel
The scanning model for translation: an update.
1989 Standout
Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors
1999
Characterization of functionally important domains in human vitamin K-dependent protein S using monoclonal antibodies.
1990
Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity.
1986
Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule
1986
Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities
1995
Effects of Disturbed Flow on Vascular Endothelium: Pathophysiological Basis and Clinical Perspectives
2011 Standout
Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V
1984
Coagulation factors V and VIII and ceruloplasmin constitute a family of structurally related proteins.
1984
Inhibition of G protein-coupled receptor signaling by expression of cytoplasmic domains of the receptor.
1994 StandoutNobel
International Staging System for Multiple Myeloma
2005 Standout
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib
2006
Works of JA Katzmann being referenced
Acute leukemia with megakaryocytic differentiation: a study of 12 cases identified immunocytochemically
1984
Multiple myeloma: circulating lymphocytes that express plasma cell antigens
1984
Monoclonal antibodies to porcine factor VIII coagulant and their use in the isolation of active coagulant protein
1982
Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma [see comments]
1993
Monoclonal antibodies to human coagulation factor V and factor Va
1983
Monoclonal antibodies to von Willebrand's factor: reactivity with porcine and human antigens
1981
Functional studies of Willebrand factor using monoclonal antibodies
1983
Monoclonal antibodies to human vitamin K-dependent protein S
1986
Monoclonal autoantibodies promote central nervous system repair in an animal model of multiple sclerosis
1994
Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma
1988
Acute leukemia with megakaryocytic differentiation: a study of 12 cases identified immunocytochemically
1984
Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma
1988
Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma [see comments]
1993
Monoclonal antibodies to von Willebrand's factor: reactivity with porcine and human antigens
1981